Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes it to our list of the Top 10 AI Infrastructure Stocks to Buy Now.

Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

A doctor in a lab coat holding a healthcare solution in their hands.

On July 10, 2025, Tempus AI, Inc. (NASDAQ:TEM) announced an update about its strategic partnership with Personalis. Under this expansion, the company added colorectal cancer to its existing commercialization agreement. This new agreement grants Tempus AI, Inc. (NASDAQ:TEM) exclusive rights to market its NeXT Personal Minimum Residual Disease (MRD) test across four oncology types through 2028. This follows the results from the VICTORI study, which showed early detection strength in CRC, which is crucial for timely treatment.

This agreement follows a period of strong momentum, where Tempus AI, Inc. (NASDAQ:TEM) reported a 75% increase in its revenue ($255.7 million) for Q1 2025. With strong profitability, the company has raised its full-year revenue guidance to $1.25 billion, having signed a $200 million data license deal with AstraZeneca and Pathos that will enhance AI model development in oncology.

Catering to over 50% of U.S. oncologists, Tempus AI, Inc. (NASDAQ:TEM) offers platforms like Insights, Lens, and Hub that combine sequencing diagnostics with algorithmic tools, powering data-driven cancer treatment decisions.

While we acknowledge the potential of TEM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Kerr Neilson’s 10 Stock Picks with Huge Upside Potential and Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates.

Disclosure: None.